StageAcq - P2P | Acquired
About Kite Pharma
Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing immunotherapies and other oncology treatments.
Missing: Kite Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Kite Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Kite Pharma
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Kite Pharma in 1 CB Insights research brief, most recently on Mar 26, 2020.
Expert Collections containing Kite Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Kite Pharma is included in 3 Expert Collections, including Synthetic Biology.
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Kite Pharma Patents
Kite Pharma has filed 71 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Immune system
Immunology, Proteins, Monoclonal antibodies, Clusters of differentiation, Ion channel toxins
Immunology, Proteins, Monoclonal antibodies, Clusters of differentiation, Ion channel toxins
Latest Kite Pharma News
Feb 17, 2023
Shaw, who joined Gilead in 2019 from Eli Lilly, helped build Kite into a leading producer of cell therapies, convincing Wall Street skeptics in the process. Published Feb. 17, 2023 A sign showing Gilead's logo. Justin Sullivan via Getty Images Top Gilead Sciences executive Christi Shaw will leave the company at the end of March after more than three years running the drugmaker’s Kite cell therapy division, Gilead annnounced Friday . Over that time, Shaw helped grow Kite into a leading producer of the complex medicines and an important contributor to Gilead’s overall business, which has long been dominated by pills for HIV and hepatitis C. Last year, sales of the Gilead’s two marketed cell therapies, approved to treat certain blood cancers, totaled nearly $1.5 billion , or about 6% of the company’s revenue outside of its COVID-19 drug Veklury. Gilead said Shaw will work with CEO Daniel O’Day and the Kite team to hand off her responsibilities while the company searches for her replacement. “Under Christi’s leadership, Kite has become a global leader in cell therapy,” said O’Day, who hired Shaw from Eli Lilly, where she had run the Indianapolis pharmaceutical company’s biologic medicines division. Prior to Lilly, Shaw worked at Novartis in several high-profile executive roles before stepping down in 2016 to care for her sister , who had multiple myeloma. “My journey with Kite has truly been the highlight of my career due to the very personal nature of cell therapy and the curative potential that it can provide patients with certain blood cancers,” Shaw said in Gilead’s statement. “There is no good time to end a labor of love, but I feel I have accomplished what I came to do.” She leaves Kite in a secure position, with sales growing strongly following the Food and Drug Administration’s April 2022 approval of Gilead’s cell therapy Yescarta for earlier use in treating large B-cell lymphoma. The clearance, a first in the field, significantly increased the number of people eligible for the therapy, which previously was reserved only for the sickest patients. She’s also overseen an expansion of Kite’s manufacturing capabilities , which are critical for producing personalized cellular medicines. The kind of cell therapy Kite specializes in, known as CAR-T, requires immune cells to be extracted from each individual patient, reengineered in a laboratory to more effectively target cancer and then reinfused. The multi-week process involves careful managing of supply chains spanning states, countries and oceans. “Our focus is really on the supply side and being able to ensure that we have the capacity to provide for patients,” Shaw said on a recent earnings call for Gilead. Notably, Kite has avoided some of the manufacturing problems that have bedeviled other large companies in the field, like Novartis . According to Gilead, Kite has now treated nearly 13,000 patients globally with Yescarta and its other cell therapy, Tecartus, which is approved for mantle cell lymphoma and acute lymphoblastic leukemia. Investors, who were previously skeptical of Gilead’s foray into cell therapy, have increasingly given the company more credit for Kite. Initially, many on Wall Street criticized Gilead for overpaying to acquire Kite Pharma in a $12 billion deal in 2017 that brought cell therapy into the company’s business. Since then, Gilead has made oncology a major focus , investing heavily in acquisitions, partnerships and research collaborations to build a cancer drug pipeline that’s now broader than what it has in testing for viral diseases. Whoever Gilead brings in to replace Shaw will face several challenges, however, among them growing competition. The company is behind rivals Bristol Myers Squibb and Johnson & Johnson in bringing to market a cell therapy for multiple myeloma, the other cancer beyond lymphoma and leukemia for which the treatments have proved strikingly effective. Gilead will also need to fend off challenges from smaller biotechs that seek to improve on existing CAR-T therapies by using donor, rather than patient cells, as well as by using newer techniques to improve their safety and efficacy. Recommended Reading
Kite Pharma Frequently Asked Questions (FAQ)
Where is Kite Pharma's headquarters?
Kite Pharma's headquarters is located at 2225 Colorado Avenue, Foster City.
What is Kite Pharma's latest funding round?
Kite Pharma's latest funding round is Acq - P2P.
How much did Kite Pharma raise?
Kite Pharma raised a total of $85.25M.
Who are the investors of Kite Pharma?
Investors of Kite Pharma include Gilead Sciences, Two River Group Holdings, TPG Capital, Alta Partners, Commercial Street Capital and 7 more.
Who are Kite Pharma's competitors?
Competitors of Kite Pharma include Luminary Therapeutics and 4 more.
Compare Kite Pharma to Competitors
Tizona Therapeutics is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system's function. In cancer, tumor cells evade recognition by controlling cells that suppress the proper function of the immune system. In autoimmune disease, the immune system attacks "self" tissues in the body due to insufficient regulation. Tizona's therapies are designed to regulate these suppressive cells, thereby either activating the body's ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. The company was founded in 2015 and is based in South San Francisco, California.
Evive Biotech is an integrated biotech company developing therapeutic biologics. Products under development are mainly aimed at unsolved medical problems, such as oncology, inflammation, and autoimmune diseases. The company was formerly known as Generon Biomed, Inc. and changed its name to Evive Biotech in June 2020. The company was founded in 2004 and is based in Singapore, Singapore.
BioViva USA builds gene therapies that work at the cellular level to alleviate those diseases caused by cellular degeneration and genetic disorders. BioViva works to advance research and therapeutics throughout the world to accomplish cures for disease models, improve resilience to cellular defects, as well as to achieve physical improvements in the human body. It was founded in 2015 and is based in Bainbridge Island, Washington.
Theracell Advanced Biotechnology provides personalized and precision medicine, enabling individualized treatment with improved outcome. It offers advanced therapy medicinal products (ATMP), which are comprised of gene therapy, somatic cell therapy, and tissue engineered products. Based on viable cells or tissues, their pharmacological, immunologic or metabolic action should be considered as the principal mode of action. The company's therapeutic portfolio spans the areas of orthopedics, dermatology, nephrology, immuno-oncology, and tissue repair and regeneration. Through strategic partnerships Theracell Advanced Biotechnology participates in the global vision of the realization of personalized medicine tailored to individual patient needs.
ImCheck Therapeutics designs and develops immunotherapy antibodies positioned at the crossroads of two high-potential immunological fields: g9d2 T cells and a novel super-family of immunomodulators, butyrophilins. Due to their mechanism of action, and notably their ability to simultaneously modulate innate and adaptive immunity, ImCheck's activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and when used in combination to overcome the resistance to this group of agents. In addition, preclinical experiments with ImCheck’s antagonist antibodies have demonstrated potential as treatments for a wide range of autoimmune diseases. ImCheck Therapeutics was founded in 2015 and is based in Marseille, France.
Luminary is a clinical-stage allogeneic cell therapy company focused on combining advanced receptor design with cell engineering to overcome antigen escape and T-cell dysfunction. Its therapeutic solutions include BAFF CAR-T, Universal Receptor, and a non-viral allogeneic platform. The company was founded in 2019 and is based in Minneapolis, Minnesota.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.